- The Redomicile is anticipated to provide greater opportunities to enhance long-term value for securityholders, simplify commercialization efforts and monetization opportunities for our product candidates, and provide greater comparability to our peers.
- Leading independent proxy advisory firms, Institutional Shareholder Services and Glass Lewis, have both recommended that shareholders vote FOR the Redomicile resolution.
- Vote FOR the Zymeworks Redomicile before the deadline of 9:00 a.m., Pacific Time, on October 5, 2022. For help voting, contact Kingsdale Advisors at 1-855-476-7981 (within North America) or at 1-416-867-2272 (outside North America), or at contactus@kingsdaleadvisors.com.
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reminds shareholders that the deadline for voting FOR the Company’s plan to become a Delaware corporation (the “Redomicile”) is 9:00 a.m., Pacific Time, on October 5, 2022. If you require assistance voting your proxy, please contact Kingsdale Advisors at 1-855-476-7981 (within North America), or at 1-416-867-2272 (outside North America), or by email at contactus@kingsdaleadvisors.com.
“We believe that the Redomicile is in the best interest of Zymeworks,” said Kenneth Galbraith, Chair and CEO of Zymeworks. “We believe the Redomicile will provide greater opportunities to enhance long-term value for securityholders, simplify commercialization efforts and monetization opportunities for our product candidates, and provide greater comparability to our peers. We expect that these factors will better position Zymeworks for future growth.”
The upcoming special meeting of Zymeworks securityholders will be held at the Pearl Room, Fairmont Pacific Rim, 1038 Canada Place, Vancouver, BC V6C 0B9 on October 7, 2022 at 9:00 a.m., Pacific Time. Zymeworks urges securityholders to vote before the deadline of 9:00 a.m., Pacific Time, on October 5, 2022.
